Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.
Lanman TA, Youssef G, Huang R, Rahman R, DeSalvo M, Flood T, Hassanzadeh E, Lang M, Lauer J, Potter C, Jiao A, Pan I, Cahill DP, Lan Z, Ospina JP, Nakhate V, Stec NE, Shi D, Bi WL, McBrayer SK, Arrillaga-Romany I, Lee EQ, Chukwueke UN, Nayak L, Forst DA, Gerstner ER, Jordan JT, Dietrich J, Miller J, Batchelor TT, Reardon DA, Wen PY, Gonzalez Castro LN.
Lanman TA, et al. Among authors: batchelor tt.
Neurooncol Adv. 2024 Dec 19;7(1):vdae227. doi: 10.1093/noajnl/vdae227. eCollection 2025 Jan-Dec.
Neurooncol Adv. 2024.
PMID: 39911703
Free PMC article.